Definium Therapeutics Doses First Patient in Second Phase 3 DT120 ODT MDD Trial
DFTX•Definium Therapeutics has dosed the first patient in its second global Phase 3 trial of DT120 orally disintegrating tablet for major depressive disorder. The study advances the company’s lead antidepressant candidate toward pivotal efficacy and safety evaluation required for potential regulatory approval.
1. Phase 3 Trial Initiation
Definium Therapeutics has enrolled and dosed the initial patient in the second pivotal Phase 3 study of DT120 orally disintegrating tablet in adults with major depressive disorder, marking a significant clinical milestone for its lead compound.
2. Clinical Development Outlook
This trial will build on the company’s earlier Phase 3 initiation and aims to provide comprehensive safety and efficacy data necessary for discussions with regulatory authorities regarding potential New Drug Application submissions.
